Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment of diabetic retinopathy with whole human post-translationally modified anti-VEGF Fab

A retinopathy, diabetic technology for the treatment of diabetic retinopathy with a fully human post-translationally modified anti-VEGF Fab

Pending Publication Date: 2022-05-13
再生生物股份有限公司
View PDF46 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, for patients with very severe NPDR, the risk of progression to high-risk PDR increases to 75% within 1 year

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of diabetic retinopathy with whole human post-translationally modified anti-VEGF Fab
  • Treatment of diabetic retinopathy with whole human post-translationally modified anti-VEGF Fab
  • Treatment of diabetic retinopathy with whole human post-translationally modified anti-VEGF Fab

Examples

Experimental program
Comparison scheme
Effect test

example 2

[0416] 6.2 Example 2: Ranibizumab cDNA-based vector

[0417] A ranibizumab Fab cDNA-based vector comprising a transgene comprising the ranibizumab Fab light and heavy chain cDNAs (not encoding the portion of SEQ ID NO. 12 and 13 of the signal peptide, respectively) was constructed. Transgenes also include nucleic acids comprising a signal peptide selected from the group listed in Table 1. The nucleotide sequences encoding the light and heavy chains are separated by an IRES element or 2A cleavage site to generate a bicistronic vector. Optionally, the vector additionally includes a hypoxia-inducible promoter.

example 3

[0418] 6.3 Example 3: Vectors based on hyperglycosylated bevacizumab Fab cDNA

[0419] A hyperglycosylated bevacizumab Fab cDNA-based vector comprising a transgene comprising the bevacizumab Fab of the light and heavy chain cDNA sequences (SEQ ID NO. 10 and 11, respectively) was constructed. A portion having a mutation in the sequence encoding one or more of the following mutations: L118N (heavy chain), E195N (light chain) or Q160N or Q160S (light chain). Transgenes also include nucleic acids comprising a signal peptide selected from the group listed in Table 1. The nucleotide sequences encoding the light and heavy chains are separated by an IRES element or 2A cleavage site to generate a bicistronic vector. Optionally, the vector additionally includes a hypoxia-inducible promoter.

[0420] 6.4 Example 4: Hyperglycosylated ranibizumab cDNA based vector

[0421] A vector based on the hyperglycosylated ranibizumab Fab cDNA comprising the transgene comprising the ranibizumab li...

example 7

[0476] 6.7 Example 7: Open-label Phase 2a Dose Evaluation of Construct II Gene Therapy in Participants with Diabetic Retinopathy

[0477] This example is an updated version of Example 6 and provides an overview of the Phase 2a dose evaluation of Construct II gene therapy in participants with diabetic retinopathy (DR). Continued stable expression of the construct II transgene product following a single gene therapy treatment for DR could potentially reduce the treatment burden of currently available therapies while preserving vision, its favorable benefit:risk spectrum. The current proof-of-concept study was designed to evaluate the safety and efficacy of Construct II gene therapy at 2 different dose levels in participants with DR.

[0478] 6.7.1 Purpose and Endpoints

[0479] Table 6: Primary Purposes and Endpoints and Secondary Purposes and Endpoints

[0480]

[0481]

[0482]

[0483] AAV8 = adeno-associated virus serotype 8; AE = adverse event; CI-DME = centrally...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Described are methods for using a fully human post-translationally modified (HuPTM) monoclonal antibody ("mAb") or antigen binding fragment of mAb against human vascular endothelial growth factor ("hVEGF"), such as, for example, an antigen binding fragment of mAb. The present invention relates to compositions and methods for delivery of a fully human glycosylated (HuGly) anti-hVEGF antigen binding fragment to the retinal / vitreous humor in the eye of a human subject diagnosed with diabetic retinopathy. The invention relates to compositions and methods for the delivery of a fully human glycosylated (HuGly) anti-hVEGF antigen binding fragment to the retinal / vitreous humor in the eye of a human subject diagnosed with diabetic retinopathy.

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Application No. 62 / 891,799, filed August 26, 2019, U.S. Provisional Application No. 62 / 902,352, filed September 18, 2019, and U.S. Provisional Application No. 63, filed April 2, 2020 / 004,258, the contents of which are incorporated herein by reference in their entirety. [0003] References to Sequence Listings Submitted Electronically [0004] This application incorporates by reference the Sequence Listing entitled "12656-127-228_Sequence_Listing.TXT," which was created on August 12, 2020 and is 97,447 bytes in size, as a text file filed with this application. technical field [0005] A fully human post-translationally modified (HuPTM) monoclonal antibody ("mAb") or an antigen-binding fragment of a mAb directed against vascular endothelial growth factor ("VEGF") is described—for example, a fully human glycosylated (HuGly) Anti-VEGF Antigen-Binding Fragment - delivered to the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P27/02C07K16/22
CPCA61K39/3955C07K16/22A61P27/02C07K2317/41C07K2317/55A61K2039/5256C12Q1/686A61B3/10A61B5/01C12N2750/14143A61K2039/505A61K38/1866
Inventor S·J·帕科拉S·范艾维伦J·I·尤S·M·帕特尔A·A·加内卡尔A·R·欧贝里K·R·欧文-帕克D·T·柯蒂斯
Owner 再生生物股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com